

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Ketalar 10mg/ml Solution for Injection/Infusion

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Ketamine hydrochloride equivalent to 10 mg ketamine base per ml.
A 20 ml solution contains ketamine hydrochloride equivalent to 200 mg ketamine base.

Excipient with known effect:

Ketalar 10mg/ml contains 53 mg of sodium per 20 ml of solution.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for injection or infusion
A clear, colourless, aqueous solution for injection or infusion.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Ketamine is indicated in children and in adults.

1. As an anaesthetic agent for short diagnostic and surgical procedures which do not require skeletal muscle relaxation.
2. For the induction of anaesthesia prior to the administration of other general anaesthetic agents.
3. To supplement other anaesthetic agents.

Specific areas of application or types of procedures:

1. When the intramuscular route of administration is more convenient.
2. Debridement, painful dressings, and skin grafting in burned patients, as well as other superficial surgical procedures.
3. For certain neurological, radiodiagnostic and therapeutic procedures in children to abolish movement.
4. When airway control is difficult.

Note: Ketamine should be used only with caution in surgical procedures involving pharynx, larynx or trachea as it increases salivary and tracheo-bronchial secretions and does not reliably suppress pharyngeal or laryngeal reflexes.

4.2 Posology and method of administration

For intravenous infusion, intravenous injection or intramuscular injection.

NOTE: All doses are given in terms of ketamine base

Ketalar is not indicated nor recommended for long term use (see sections 4.1 and 4.4).

Adults, elderly (over 65 years) and children

For surgery in elderly patients ketamine has been shown to be suitable either alone or supplemented with other anaesthetic agents.

Preoperative preparations

1. Ketalar has been safely used alone when the stomach was not empty. However, since it may also cause vomiting and since the need for supplemental agents and muscle relaxants cannot be predicted, when preparing for elective surgery it is advisable that nothing be given by mouth for at least six hours prior to anaesthesia.
2. Ketamine increases salivation. Premedication with an anticholinergic agent (e.g. atropine, hyoscine, glycopyrrolate) or another drying agent should be given at an appropriate interval prior to induction to reduce ketamine-induced hypersalivation (see section 4.8).
3. Midazolam, diazepam, lorazepam, or flunitrazepam used as a premedicant or as an adjunct to ketamine, have been effective in reducing the incidence of emergence reactions.

Onset and duration

As with other general anaesthetic agents, the individual response to Ketalar is somewhat varied depending on the dose, route of administration, age of patient, and concomitant use of other agents, so that dosage recommendation cannot be absolutely fixed. The dose should be titrated against the patient's requirements.

Because of rapid induction following intravenous injection, the patient should be in a supported position during administration. An intravenous dose of 1 – 2 mg/kg of bodyweight usually produces surgical anaesthesia within 30 seconds – 1 minute after injection and the anaesthetic effect usually lasts 5 to 10 minutes. An intramuscular dose of 10 mg/kg of bodyweight usually produces surgical anaesthesia within 3 to 4 minutes following injection and the anaesthetic effect usually lasts 12 to 25 minutes. Return to consciousness is gradual.

A. Ketalar as the sole anaesthetic agent

Intravenous Infusion

The use of Ketalar by continuous infusion enables the dose to be titrated more closely, thereby reducing the amount of drug administered compared with intermittent administration. This results in a shorter recovery time and better stability of vital signs.

A solution containing 1mg/ml of ketamine in dextrose 5% or sodium chloride 0.9% is suitable for administration by infusion.

If fluid restriction is required, ketamine can be added to 250 ml infusion fluid to provide a ketamine concentration of 2 mg/ml. Ketamine vials in the 10 mg/ml concentration are not recommended for dilution.

Induction

An infusion corresponding to 0.5 – 2 mg/kg as total induction dose.

Maintenance of anaesthesia

Anaesthesia may be maintained using a microdrip infusion of 10 - 40 microgram/kg/min (approximately 1 – 3 mg/min).

The rate of infusion will depend on the patient's reaction and response to anaesthesia. The dosage required may be reduced when a long acting neuromuscular blocking agent is used.

Intermittent Injection

Induction

Intravenous Route

The initial dose of Ketalar administered intravenously may range from 1mg/kg to 4.5 mg/kg. The average amount required to produce 5 to 10 minutes of surgical anaesthesia has been 2.0mg/kg. It is recommended that intravenous administration be accomplished slowly (over a period of 60 – 120 seconds). More rapid administration may result in respiratory depression and enhanced pressor response.

Dosage in Obstetrics

In obstetrics, for vaginal delivery or in caesarean section, intravenous doses ranging from 0.2 to 1.0 mg/kg are recommended (see section 4.6 Fertility, pregnancy and lactation). However, data are lacking for maintenance infusion of ketamine in the parturient population and dosing recommendations cannot be made.

Intramuscular Route

The initial dose of Ketalar administered intramuscularly may range from 6.5 mg/kg to 13 mg/kg, usually 10 mg/kg. A low initial intramuscular dose of 4 mg/kg has been used in diagnostic manoeuvres and procedures not involving intensely painful stimuli. A dose of 10 mg/kg will usually produce 12 to 25 minutes of surgical anaesthesia.

Hepatic Insufficiency

Dose reductions should be considered in patients with cirrhosis or other types of liver impairment (see section 4.4).

Dosage in Obstetrics

Data are lacking for intramuscular injection in the parturient population, and dosing recommendations cannot be made. Available pharmacokinetic data are presented in section 5.2.

Maintenance of anaesthesia

Lightening of anaesthesia may be indicated by nystagmus, movements in response to stimulation, and vocalization. Anaesthesia is maintained by the administration of additional doses of Ketalar by either the intravenous or intramuscular route. However, data are lacking regarding the maintenance dosage of ketamine in the parturient population and dosing recommendations cannot be made.

Each additional dose is from ½ to the full induction dose recommended above for the route selected for maintenance, regardless of the route used for induction.

The larger the total amount of Ketalar administered, the longer will be the time to complete recovery.

Purposeless and tonic-clonic movements of extremities may occur during the course of anaesthesia. These movements do not imply a light plane and are not indicative of the need for additional doses of the anaesthetic.

B. Ketalar as induction agent prior to the use of other general anaesthetics

Induction is accomplished by a full intravenous or intramuscular dose of Ketalar as defined above. If Ketalar has been administered intravenously and the principal anaesthetic is slow-acting, a second dose of Ketalar may be required 5 to 8 minutes following the initial dose. If Ketalar has been administered intramuscularly and the principal anaesthetic is rapid-acting, administration of the principal anaesthetic may be delayed up to 15 minutes following the injection of Ketalar.

C. Ketalar as supplement to anaesthetic agents

Ketalar is clinically compatible with the commonly used general and local anaesthetic agents when an adequate respiratory exchange is maintained. The dose of Ketalar for use in conjunction with other anaesthetic agents is usually in the same range as the dosage stated above; however, the use of another anaesthetic agent may allow a reduction in the dose of Ketalar.

Management of patients in recovery

Following the procedure the patient should be observed but left undisturbed. This does not preclude the monitoring of vital signs. If, during the recovery, the patient shows any indication of emergence delirium, consideration may be given to the use of diazepam (5 to 10 mg I.V. in an adult). A hypnotic dose of a thiobarbiturate (50 to 100 mg I.V.) may be used to terminate severe emergence reactions. If any one of these agents is employed, the patient may experience a longer recovery period.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Ketalar is contraindicated in persons in whom an elevation of blood pressure would constitute a serious hazard (see section 4.8). Ketalar should not be used in patients with eclampsia or pre-eclampsia, severe coronary or myocardial disease, C.V.A. or cerebral trauma. Known history of psychiatric problems.

4.4 Special warnings and precautions for use

To be used only in hospitals by or under the supervision of experienced medically qualified anaesthetists except under emergency conditions.

As with any general anaesthetic agent, resuscitative equipment should be available and ready for use.

Use of this agent should always be preceded by appropriate doses of atropine, hyoscine or another drying agent.

Ketalar is chemically incompatible with barbiturates and diazepam. Therefore, these should not be mixed in the same syringe or infusion fluid.

Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with Ketalar.

Emergence delirium phenomena may occur during the recovery period. The incidence of these reactions may be reduced if verbal and tactile stimulation of the patient is minimised during the recovery period. This does not preclude the monitoring of vital signs.

The psychological manifestations vary in severity between pleasant dream-like states, vivid imagery, hallucinations, nightmares and emergence delirium (often consisting of dissociative or floating sensations). In some cases these states have been accompanied by confusion, excitement, and irrational behaviour which a few patients recall as an unpleasant experience (see section 4.8).

Because pharyngeal and laryngeal reflexes usually remain active, mechanical stimulation of the pharynx should be avoided unless muscle relaxants, with proper attention to respiration, are used.

The high plasma concentration following intravenous administration has been shown to depress respiration and the pharyngolaryngeal reflexes for a brief period. Slow injection of the dilute solution is required to minimize these effects. Aspiration of contrast medium has been reported during Ketalar anaesthesia under experimental conditions (Taylor, P A and Towey, R M, Brit. Med. J. 1971, 2: 688) and, although in clinical practice aspiration is seldom a problem, the possibility should be borne in mind.

Due to substantial increase in myocardial oxygen consumption, Ketalar should be used with caution in patients with hypovolaemia, dehydration, or cardiac disease, especially coronary artery disease (e.g. congestive heart failure, myocardial ischemia and myocardial infarction). In addition ketamine should be used with caution in patients with mild-to-moderate hypertension and tachyarrhythmias.

Ketalar should be used with caution in patients with pulmonary or upper respiratory infection (Ketalar sensitizes the gag reflex, potentially causing laryngospasm).

Cardiac function should be continually monitored during the procedure in patients found to have hypertension or cardiac decompensation.

Elevation of blood pressure begins shortly after the injection of Ketalar, reaches a maximum within a few minutes and usually returns to preanaesthetic values within 15 minutes after injection. The median peak rise of blood pressure in clinical studies has ranged from 20 to 25 percent of preanaesthetic values. Depending on the condition of the patient, this elevation of blood pressure may be considered a beneficial effect, or in others, an adverse reaction.

Since an increase in cerebrospinal fluid pressure has been reported during Ketalar anaesthesia, Ketalar should be used with special caution in patients with preanaesthetic elevated cerebrospinal fluid pressure.

Respiratory depression may occur with overdosage of Ketalar, in which case supportive ventilation should be employed. Mechanical support of respiration is preferred to the administration of analeptics.

The intravenous dose should be administered over a period of 60 – 120 seconds. More rapid administration may result in transient respiratory depression or apnoea and enhanced pressor response.

In surgical procedures involving visceral pain pathways, Ketalar should be supplemented with an agent which obtunds visceral pain.

Ketamine is metabolized in the liver and hepatic clearance is required for termination of clinical effects. Abnormal liver function tests associated with ketamine use have been reported, particularly with extended use (>3 days) or drug abuse. A prolonged duration of action may occur in patients with cirrhosis or other types of liver impairment. Dose reductions should be considered in these patients.

Use with caution in the chronic alcoholic and the acutely alcohol-intoxicated patient.

When Ketalar is used on an outpatient basis, the patient should not be released until recovery from anaesthesia is complete and then should be accompanied by a responsible adult.

Patients should be cautioned that driving a car, operating hazardous machinery or engaging in hazardous activities should not be undertaken for 24 hours or more after anaesthesia.

Ketalar should be used with caution in patients with:

- Chronic alcoholic and the acutely alcohol-intoxicated patients.
- Increased intraocular pressure (e.g. glaucoma) as the pressure may increase significantly after a single dose of ketamine.
- Neurotic traits or psychiatric illness (e.g. schizophrenia and acute psychosis).
- Acute intermittent porphyria.
- Seizures.
- Hyperthyroidism or patients receiving thyroid replacement (increased risk of hypertension and tachycardia).
- Intracranial mass lesions, a presence of head injury, globe injuries or hydrocephalus.

Long-Term Use

Ketalar is not indicated nor recommended for long term use (see sections 4.1 and 4.2).

Cases of cystitis, including haemorrhagic cystitis, acute kidney injury, hydronephrosis, and ureteral disorders have been reported in patients being given ketamine on a long term basis, especially in the setting of ketamine abuse. These adverse reactions develop in patients receiving long term ketamine treatment after a time ranging from 1 month to several years.

Hepatotoxicity such as mixed liver injury, cholestatic liver injury and biliary dilation has also been reported in patients with extended use (> 3 days). See section 4.8.

Drug Abuse and Dependence

Ketalar has been reported as being a drug of abuse. Reports suggest that ketamine produces a variety of symptoms including, but not limited to, flashbacks, hallucinations, dysphoria,

anxiety, insomnia, or disorientation (see section 4.8). Other adverse effects have also been reported: see “Long-Term Use”.

If used on a daily basis for a few weeks, dependence and tolerance may develop, particularly in individuals with a history of drug abuse and dependence. Therefore the use of Ketalar should be closely supervised and it should be prescribed and administered with caution.

Excipient information

Ketalar 10mg/ml contains 53 mg of sodium in each vial, equivalent to 2.65% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

4.5 Interaction with other medicinal products and other forms of interaction

The use of barbiturates or opiate agonists concurrently with ketamine may prolong the recovery period, as may also benzodiazepines used as premedication.

Barbiturates and Ketalar, being chemically incompatible because of precipitate formation, should not be injected from the same syringe.

Other general anaesthetics block the centrally mediated cardiovascular stimulant properties of ketamine. Significant cardiovascular depression increased risk of developing bradycardia, hypotension or decreased cardiac output have occurred with concurrent use of halothane or enflurane anaesthesia.

Diazepam is known to increase the half-life of ketamine and prolongs its pharmacodynamic effects. Dose adjustments may therefore be needed. Concurrent use of diazepam or other benzodiazepines will increase plasma levels and reduce the clearance rate of ketamine.

Ketamine may potentiate the neuromuscular blocking effects of atracurium and tubocurarine, including respiratory depression with apnea.

The use of halogenated anaesthetics concomitantly with ketamine can lengthen the elimination half life of ketamine and delay recovery from anaesthesia. Concurrent use of ketamine (especially high doses or when rapidly administered) with halogenated anaesthetics can increase the risk of developing bradycardia, hypotension or decrease cardiac output.

The use of ketamine with other central nervous system (CNS) depressants (e.g. ethanol, phenothiazines, sedating H₁- blockers or skeletal muscle relaxants) can potentiate CNS depression and/or increase the risk of developing respiratory depression. Reduced doses of ketamine may be required with concurrent administration of other anxiolytics, sedatives and hypnotics.

Ketamine has been reported to antagonize the hypnotic effect of thiopental.

Concomitant use of antihypertensive agents and ketamine increases the risk of developing hypotension.

Sympathomimetics (directly or indirectly acting) and vasopressin may enhance the sympathomimetic effects of ketamine.

Concomitant use with ergometrine may lead to an increase in blood pressure.

When ketamine and theophylline or aminophylline are given concurrently, a clinically significant reduction in the seizure threshold may be observed. Unpredictable extensor-type seizures have been reported with concurrent administration of these agents.

Halothane used concomitantly slows distribution and redistribution of ketamine and inhibits its hepatic metabolism.

Concurrent use of nitrous oxide will reduce the required dose of ketamine.

The concomitant use of ketamine with gallamine will lead to tachycardia, and with pancuronium to hypertension. Neither relaxant should be used with ketamine.

Ketamine should be used cautiously in patients receiving thyroid hormone because of the increased risk of hypertension and tachycardia.

Drugs that inhibit CYP3A4 enzyme activity generally decrease hepatic clearance, resulting in increased plasma concentration of CYP3A4 substrate medications, such as ketamine. Co-administration of ketamine with drugs that inhibit CYP3A4 enzyme may require a decrease in ketamine dosage to achieve the desired clinical outcome.

Drugs that induce CYP3A4 enzyme activity generally increase hepatic clearance, resulting in decreased plasma concentration of CYP3A4 substrate medications, such as ketamine. Co-administration of ketamine with drugs that induce CYP3A4 enzyme may require an increase in ketamine dosage to achieve the desired clinical outcome.

4.6 Fertility, pregnancy and lactation

Pregnancy

Ketamine crosses the placenta. This should be borne in mind during operative procedures in pregnancy. No controlled clinical studies in pregnancy have been conducted. The safe use in pregnancy has not been established, and such use is not recommended, with the exception of administration during surgery for abdominal delivery or vaginal delivery.

Studies in animals have shown reproductive toxicity (see section 5.3).

Some neonates exposed to ketamine at maternal intravenous doses ≥ 1.5 mg/kg during delivery have experienced respiratory depression and low Apgar scores requiring newborn resuscitation.

Marked increases in maternal blood pressure and uterine tone have been observed at intravenous doses greater than 2 mg/kg.

Data are lacking for intramuscular injection and maintenance intravenous infusion of ketamine in the parturient population, and dosing recommendations cannot be made. Available intramuscular injection pharmacokinetic data are presented in section 5.2.

Breast-feeding

The safe use of ketamine during lactation has not been established, and such use is not recommended.

4.7 Effects on ability to drive and use machines

Patients should be cautioned that driving a car, operating hazardous machinery or engaging in hazardous activities should not be undertaken for 24 hours or more after anaesthesia.

4.8 Undesirable effects

The following Adverse Events have been reported:

MedDRA System Organ Class	Frequency†	Undesirable Effects
Immune system disorders	Rare	Anaphylactic reaction*
Metabolism and nutrition disorders	Uncommon	Anorexia
Psychiatric disorders	Common	Hallucination, Abnormal dreams, Nightmare, Confusion, Agitation, Abnormal behaviour
	Uncommon	Anxiety
	Rare	Delirium*, Disorientation*, Flashback*, Dysphoria*, Insomnia
Nervous system disorders	Common	Nystagmus, Hypertonia, Tonic clonic movements
Eye disorders	Common	Diplopia
	Not known	Intraocular pressure increased
Cardiac disorders	Common	Blood pressure increased, Heart rate increased
	Uncommon	Bradycardia, Arrhythmia
Vascular disorders	Uncommon	Hypotension
Respiratory, thoracic and mediastinal disorders	Common	Respiratory rate increased
	Uncommon	Respiratory depression, Laryngospasm
	Rare	Obstructive airways disorder*, Apnoea*
Gastrointestinal disorders	Common	Nausea, Vomiting
	Rare	Salivary hypersecretion*
Hepatobiliary disorders	Not known	Liver function test abnormal*, Drug induced liver injury*, **
Skin and subcutaneous tissue disorders	Common	Erythema, Rash morbilliform
Renal and urinary disorders	Rare	Haemorrhagic cystitis*, ***, Cystitis*, ***
General disorders and administration site conditions	Uncommon	Injection site pain, Injection site rash

† Common ($\geq 1/100$ to $< 1/10$); Uncommon ($\geq 1/1,000$ to $< 1/100$); Rare ($\geq 1/10,000$ to $< 1/1,000$); Not known (frequency cannot be estimated from the available data)

* ADR identified during post-marketing use.

** Extended period use (> 3 days) or drug abuse.

*** Long term use (1 month to several years), especially in the setting of ketamine abuse.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA

Pharmacovigilance. Website: www.hpra.ie

4.9 Overdose

Respiratory depression can result from an overdosage of ketamine hydrochloride. Supportive ventilation should be employed. Mechanical support of respiration that will maintain adequate blood oxygen saturation and carbon dioxide elimination is preferred to administration of analeptics.

Ketalar has a wide margin of safety; several instances of unintentional administration of overdoses of Ketalar (up to 10 times that usually required) have been followed by gradual but complete recovery.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

ATC code: N01 AX03

General anaesthetics, other

Ketamine is a rapidly acting general anaesthetic for intravenous or intramuscular use with a distinct pharmacological action. Ketamine hydrochloride produces dissociative anaesthesia characterised by catalepsy, amnesia, and marked analgesia which may persist into the recovery period. There is only slight diminution of pharyngeal-laryngeal reflexes and skeletal muscle tone may be normal or can be enhanced to varying degrees. Mild cardiac and respiratory stimulation and occasionally respiratory depression occur.

Mechanism of Action

Ketamine induces sedation, immobility amnesia, and marked analgesia. The anaesthetic state produced by ketamine has been termed 'dissociative anaesthesia' in that it appears to selectively interrupt association pathways of the brain before producing somesthetic sensory blockade. Numerous theories have been proposed to explain the effects of ketamine, including binding to N-methyl-D-aspartate (NMDA) receptors in the CNS, interactions with opiate receptors at central and spinal sites, and interaction with norepinephrine, serotonin and muscarinic cholinergic receptors. The activity on NMDA receptors may be responsible for the analgesic as well as the psychiatric (psychosis) effects of ketamine. Ketamine has sympathomimetic activity resulting in tachycardia, hypertension, increased myocardial and cerebral oxygen consumption, increased cerebral blood flow and increased intracranial and intraocular pressure. Ketamine is also a potent bronchodilator. Clinical effects observed following ketamine administration include increased blood pressure, increased muscle tone (may resemble catatonia), opening of eyes (usually accompanied by nystagmus) and increased myocardial oxygen consumption.

5.2 Pharmacokinetic properties

Absorption

Ketamine is rapidly absorbed following parenteral administration.

Distribution

Ketamine is rapidly distributed into perfused tissues including brain and placenta. Animal studies have shown ketamine to be highly concentrated in body fat, liver and lung. In humans, at an intravenous bolus dose of 2.5 mg/kg, the distribution phase of ketamine lasts about 45 minutes, with a half-life of 10 to 15 minutes, which is associated with the duration of the anaesthetic effect (about 20 minutes).

Plasma ketamine peak concentrations are about 1.8 to 2.0 microg/mL at 5 minutes after an intravenous bolus injection of a 2 mg/kg dose, and about 1.7 to 2.2 microg/mL at 15 minutes after an intramuscular injection of a 6 mg/kg dose in adults and children.

In parturients receiving an intramuscular dose of 250 mg (approximately 4.2 mg/kg), placental transfer rate of ketamine from maternal artery to umbilical vein was 47% at the time of delivery

(1.72 versus 0.75 microg/mL). Average delivery time for these parturients was 12 minutes from the time of ketamine injection to vaginal delivery of a newborn.

Biotransformation

Biotransformation takes place in the liver. Termination of anaesthetic is partly by redistribution from brain to other tissues and partly by metabolism. Ketamine undergoes hepatic N-demethylation (via the cytochrome P450 system) and hydroxylation of the cyclohexanone ring, with the formation of water-soluble conjugates which are excreted in the urine. CYP3A4 enzyme is the primary enzyme responsible for ketamine N-demethylation to norketamine in human liver microsomes; with CYP2B6 and CYP2C9 enzymes as minor contributors.

Elimination

Elimination half-life is approximately 2-3 hours, and excretion renal, mostly as conjugated metabolites.

5.3 Preclinical safety data

Animal research has shown that ketamine can induce NMDA antagonist-induced neuronal cell death in juvenile animals (apoptosis) when administered in high doses, for prolonged periods, or both. The relevance of this finding to human use is unknown.

Published studies in animals (including primates) at doses resulting in light to moderate anaesthesia demonstrate that the use of anaesthetic agents during the period of rapid brain growth or synaptogenesis results in cell loss in the developing brain that can be associated with prolonged cognitive deficiencies. The clinical significance of these nonclinical findings is not known.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium chloride
Benzethonium chloride
Water for injections

6.2 Incompatibilities

Ketalar is chemically incompatible with barbiturates and diazepam because of precipitate formation.

Therefore, these should not be mixed in the same syringe or infusion fluid.

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3 Shelf life

Unopened: 5 years.

After opening: From a microbiological point of view, unless the method of opening precludes the risk of microbial contamination, the product should be used immediately.

After dilution: Use immediately after dilution.

This product should be diluted immediately after opening.

For single use only. Discard any unused product at the end of each operating session.

6.4 Special precautions for storage

This medicinal product does not require any special temperature storage conditions. Store in the original container. Keep the vial in the outer carton in order to protect from light. Do not freeze.

6.5 Nature and contents of container

20 ml white neutral glass vial with rubber closure and aluminium flip-off cap containing 20ml of solution as 10 mg ketamine base per ml.

6.6 Special precautions for disposal and other handling

For single use only. Discard any unused product at the end of each operating session.

After opening: From a microbiological point of view, unless the method of opening precludes the risk of microbial contamination, the product should be used immediately. Discard unused product after dosing.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

This product has been shown to be compatible with dextrose 5% and sodium chloride 0.9%. See section 4.2.

7. MARKETING AUTHORISATION HOLDER

Pfizer Healthcare Ireland Unlimited Company
The Watermarque Building
Ringsend Road,
Dublin 4,
D04 K7N3,
Ireland

8. MARKETING AUTHORISATION NUMBER

PA 822/13/1

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 01 April 1980

Date of latest renewal: 01 April 2010

10. DATE OF REVISION OF THE TEXT

10/2024

Ref: KE 33_0